Target Information

Target General Information

Top

Target ID

T45598 (Former ID: TTDI01799)

Target Name

Interferon alpha (IFNA)

Synonyms

IFN-A

Click to Show/Hide

Gene Name

NO-GeName

Target Type

Successful target

[1]

Disease

[+] 2 Target-related Diseases

Human immunodeficiency virus disease [ICD-11: 1C60-1C62]

Mature B-cell leukaemia [ICD-11: 2A82]

Function

Produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase.

Click to Show/Hide

UniProt ID

NOUNIPROTAC

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 2 Approved Drugs

Alfaferone

Drug Info

Approved

Hairy cell leukaemia

[2]

Interferon alfa-n3

Drug Info

Approved

Human immunodeficiency virus infection

[3]

Clinical Trial Drug(s)

[+] 9 Clinical Trial Drugs

P1101

Drug Info

Phase 3

Polycythemia vera

[4]

Human interferon alpha oral

Drug Info

Phase 2

Hepatitis C virus infection

[5]

IFN-alpha

Drug Info

Phase 2

Hepatitis C virus infection

[6]

Interferon-alpha lozenge

Drug Info

Phase 2

Fibromyalgia

[5]

Rontalizumab

Drug Info

Phase 2

Systemic lupus erythematosus

[7]

IFN alpha kinoid

Drug Info

Phase 1/2

Human immunodeficiency virus infection

[8]

Ad-IFN-alpha

Drug Info

Phase 1

Bladder cancer

[9]

AGS-009

Drug Info

Phase 1

Systemic lupus erythematosus

[10]

NG-641

Drug Info

Phase 1

Solid tumour/cancer

[11]

Discontinued Drug(s)

[+] 3 Discontinued Drugs

PEG-Infergen

Drug Info

Discontinued in Phase 2

Hepatitis virus infection

[12]

Gene therapy, IFN-alpha

Drug Info

Terminated

Head and neck cancer

[9]

R-7025

Drug Info

Terminated

Hepatitis B virus infection

[13]

Mode of Action

[+] 2 Modes of Action

Modulator

[+] 10 Modulator drugs

Alfaferone

Drug Info

[2], [14]

Interferon alfa-n3

Drug Info

[1]

Human interferon alpha oral

Drug Info

[16]

IFN-alpha

Drug Info

[17]

Interferon-alpha lozenge

Drug Info

[18], [19]

IFN alpha kinoid

Drug Info

[20]

Ad-IFN-alpha

Drug Info

[9]

PEG-Infergen

Drug Info

[23]

Gene therapy, IFN-alpha

Drug Info

[9]

R-7025

Drug Info

[24]

Inhibitor

[+] 1 Inhibitor drugs

P1101

Drug Info

[15]

Target Affiliated Biological Pathways		Top
KEGG Pathway	[+] 15 KEGG Pathways	+
1	Cytokine-cytokine receptor interaction
2	Regulation of autophagy
3	PI3K-Akt signaling pathway
4	Toll-like receptor signaling pathway
5	RIG-I-like receptor signaling pathway
6	Cytosolic DNA-sensing pathway
7	Jak-STAT signaling pathway
8	Natural killer cell mediated cytotoxicity
9	Tuberculosis
10	Hepatitis C
11	Hepatitis B
12	Measles
13	Influenza A
14	Herpes simplex infection
15	Autoimmune thyroid disease
Reactome	[+] 4 Reactome Pathways	+
1	Interferon alpha/beta signaling
2	Regulation of IFNA signaling
3	TRAF6 mediated IRF7 activation
4	Factors involved in megakaryocyte development and platelet production
WikiPathways	[+] 3 WikiPathways	+
1	Toll-like receptor signaling pathway
2	Interferon alpha/beta signaling
3	Regulation of toll-like receptor signaling pathway

References

Top

REF 1

Clinical pipeline report, company report or official report of Hemispherx Biopharma.

REF 2

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

REF 3

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006022)

REF 4

ClinicalTrials.gov (NCT01949805) Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (PROUD-PV). U.S. National Institutes of Health.

REF 5

Clinical pipeline report, company report or official report of Amarillo Biosciences.

REF 6

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017807)

REF 7

Clinical pipeline report, company report or official report of Genentech (2011).

REF 8

ClinicalTrials.gov (NCT01058343) Safety of IFNa Kinoid in Systemic Lupus Erythematosus. U.S. National Institutes of Health.

REF 9

2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.

REF 10

ClinicalTrials.gov (NCT00960362) An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE). U.S. National Institutes of Health.

REF 11

ClinicalTrials.gov (NCT04053283) First in Human Study With NG-641, an Oncolytic Transgene Expressing Adenoviral Vector. U.S. National Institutes of Health.

REF 12

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017958)

REF 13

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018916)

REF 14

Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. Infection. 2011 Oct;39(5):433-7.

REF 15

Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015 Apr;90(4):288-94.

REF 16

Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS. 1992 Jun;6(6):563-9.

REF 17

WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same.

REF 18

Interferon-alpha. Amarillo Biosciences. Curr Opin Investig Drugs. 2002 May;3(5):693-7.

REF 19

Successful application of highly purified natural interferon alpha (multiferon) in a chronic hepatitis C patient resistant to preceding treatment approaches. Hepatogastroenterology. 2004 Sep-Oct;51(59):1476-9.

REF 20

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum. 2013 Feb;65(2):447-56.

REF 21

Emerging Therapies for Systemic Lupus Erythematosus - Focus on Targeting Interferon-alpha. Clin Immunol. 2012 June; 143(3): 210-221.

REF 22

Clinical pipeline report, company report or official report of PsiOxus Therapeutics.

REF 23

Patent CN102245599 B.

REF 24

WO patent application no. 2013,0667,53, Compositions useful for the treatment of viral diseases.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Feng ZHU

Prof. Yuzong CHEN